• Patient death prompts FDA hold on Mersana’s lead cancer ADC fiercebiotech
    July 26, 2018
    Another antibody-drug conjugate has been stalled by concerns over safety. The FDA has placed a partial hold on Mersana’s lead candidate XMT-1522 after a patient death in a phase 1 trial, causing its shares to plunge.
PharmaSources Customer Service